There is a subgroup of children with autism that appears to develop typically for a period of
time, and then loses social or language skills, or regresses. A recent study by Vargas and
co-workers at Johns Hopkins has demonstrated that this regressive type of autism is
associated with chronic brain inflammation as shown by an abnormal production of inflammatory
cytokines among other abnormalities.
This present study will test the effectiveness of minocycline, an antibiotic with
anti-inflammatory properties, in treating regressive autism. Although behavioral therapies
have improved some symptoms of autism, there are no medical treatments for the disorder, and
many children have ongoing behavioral difficulties. A medicine with anti-inflammatory
properties may be beneficial for children with regressive autism.
This will be an open-label trial, meaning all children in this study will receive
minocycline. They will also receive vitamin B6 to reduce the possible chance of side effects
of the minocycline.
Children ages 3 to 12 with regressive autism may be eligible for this study. The children
will take minocycline and vitamin B6 daily for 6 months. Prior to starting the medication and
vitamin B6, children will receive a comprehensive diagnostic assessment for autism as well as
a physical examination, medical history, and laboratory tests. Children will then receive
ongoing assessments to monitor their behavior, communication, language skills, and medical
issues at 2 weeks, and at 1, 2, 4, 6, and 12 months. Children who respond to the treatment
will receive an additional 3 months of minocycline and vitamin B6.